At low dose of 3 mg kg-1, four out of six mice treated with Pembrolizumab-IL-15Rα-IL-15 were free of tumor development, while tumor sizes of the other two mice were much smaller than that of control. The gene discussed is IL15RA; the disease is neoplasm.